摘要
目的:探讨布地奈德联合孟鲁司特钠治疗肺炎支原体肺炎(MPP)患儿的疗效及其对患儿肺功能和炎性细胞因子的影响。方法:选取2016年1-4月我院儿科收治的MPP患儿106例,随机分为观察组和对照组各53例。两组患儿入院后均给予祛痰、平喘、抗感染等常规治疗,对照组患儿同时给予布地奈德治疗,观察组患儿在对照组治疗基础上联用孟鲁司特钠,疗程均为10 d。治疗前后采用酶联免疫吸附法(ELISA)检测血清白细胞介素(IL)-6、IL-8、IL-10及肿瘤坏死因子-α(TNF-α)水平,采用肺功能监测仪检测潮气量(VT)、达峰时间比(TPTEF/TE)、呼出25%潮气量时的瞬间流速与呼气峰流速比(TEF25/PTEF)。比较两组总有效率及不良反应发生率。结果:治疗后,两组患儿IL-6、IL-8、TNF-α水平均降低,IL-10水平均升高,VT、TPTEF/TE、TEF25/PTEF均明显改善,且治疗时间越长改善越明显(P均<0.05),观察组患儿改善程度均优于对照组(P均<0.05)。观察组总有效率92.45%,高于对照组的81.13%(P<0.05),两组不良反应发生率比较差异无统计学意义(P>0.05)。结论:布地奈德联合孟鲁司特钠可有效改善MPP患儿的肺功能,降低血清炎性细胞因子水平,提高临床疗效,且不会增加不良反应,安全性较好。
Objective： To investigate the clinical effect of budesonide combined with montelukast in the treatment of children with Mycoplasma pneumoniae pneumonia （MPP） and its effects on pulmonary function and inflammatory cytokines. Methods： A total of 106 children with MPP in our hospital from January to April 2016 were collected and randomly assigned into observation group and control group with 53 children in each group. All children received expectorant, anti-asthmatic and anti-infection therapy. Children in the control group received budesonide treatment on the basis of primary treatment. Children in the observation group received montelukast sodium on the basis of control group. Before and after treatment, the levels of IL-6, IL-8, IL-10, TNF-α were detected by ELISA assay. VT, TPTEF/TE, TEF25/PTEF were detected by pulmonary function monitor. The total effective rate and adverse reaction rate were compared between the two groups. Results： After treatment, the levels of IL-6, IL-8, TNF-α of two groups were significantly decreased, the levels of IL-10 were significantly increased, the VT, TPTEF/TE, TEF25/PTEF were significantly improved, along with the treatment time extension increased more significantly （ P〈0.05 ） , and the observation group improved more than the control group （ P〈0.05 ）. The total effective rate of the observation group was significantly higher than that of the control group （92.45% vs 81.13% , P〈0.05）, while there was no significant difference in the incidence of adverse reactions between the two groups （ P 〉 O. 05 ）. Conclusion： Budesonide combined with montelukast sodium can effectively improve pulmonary function, reduce serum inflammatory cytokines levels, improve clinical total effective rate and not increase adverse reaction rate.
出处
《儿科药学杂志》
CAS
2017年第5期23-25,共3页
Journal of Pediatric Pharmacy
关键词
肺炎支原体肺炎
布地奈德
孟鲁司特钠
肺功能
炎性细胞因子
Mycoplasma pneumonine pneumonia
budesonide
montelukast sodium
pulmonary function
inflammatory cytokines
